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Indoleamine 2,3-dioxygenase (IDO), which catalyzes the initial and rate-limiting step in 
the tryptophan catabolism along the kynurenine pathway, is an immunosuppressive 
enzyme that can lead to T cell anergy, apoptosis and potential induction of regulatory T 
cells (Treg cells). This discovery has led to the development of several IDO inhibitors 
including NLG919, an immunotherapy drug that targets IDO with high efficacy, into the 
clinical trial for treating solid tumor. Our goal is to develop PEG derivatized NLG as a 
functional carrier for specifically delivering anticancer agents to the tumor site to 
stimulate immune response and eliminate systemic toxicity. Previously, our group has 
developed a PEG2K-Fmoc-NLG micellar system that can effectively deliver anticancer 
drug Paclitaxel (PTX) and synergize with chemotherapy to reduce tumor growth. One 
major limitation with this approach is the feedback mechanism following NLG-mediated 
inhibition of IDO, which subsequently leads to the up-regulation of IDO expression. In 
addition, the mRNA expression of IDO can be further enhanced by PTX treatment.  For 
long-term treatment, increased dose of this formulation would be necessary to maintain 
the same effect for treating cancer. The focus of our study is to identify a compound that 
can effectively inhibit the expression of IDO at transcriptional level and develop an 
improved PEG-NLG-based carrier for codelivery of the compound and a 
chemotherapeutic agent such as PTX. 
 
 v 
In this thesis, the first aim was to examine the effect on IDO expression by several 
anticancer drug treatments. qRT-PCR analysis results show that several anticancer drugs 
including Paclitaxel, Doxorubicin and Dasatinib can up-regulate IDO expression while 
Imatinib (Gleevec®) exhibits the opposite effect. The second aim was to synthesize 
PEG5K-(Fmoc-NLG)2 as an improved dual functional carrier for co-delivery of Paclitaxel 
and Imatinib. PEG5K-(Fmoc-NLG)2 was successfully synthesized through 6 steps. The 
product at each step was confirmed by NMR. The third aim was focused on the 
characterization of our micellar system and the fourth aim was to examine the in vivo 
therapeutic efficacy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 vi 
TABLE OF CONTENTS 
 
 
1. INTRODUCTION......................................................................................................... 1 
1.1 Limitations of current anticancer drugs and effective drug delivery system for 
cancer treatment. .......................................................................................................... 1 
1.2 Stimulated immune response by conventional chemotherapy. .......................... 2 
1.3 Immune checkpoints modulate immune escape during cancer progression. .... 2 
1.4 Indoleamine-2,3-dioxygenase (IDO) can be used as one therapeutic target to 
enhance immune response. ........................................................................................... 3 
1.5 PEG-Fmoc-NLG conjugates as dual-function carriers for cancer targeted 
delivery. .......................................................................................................................... 4 
1.6 IDO expression inhibitor can work synergistically with PEG detrivatised NLG 
based micellar system. .................................................................................................. 4 
1.7 Overview of thesis. .................................................................................................. 6 
2. MATERIALS AND METHODS ................................................................................. 7 
2.1 Materials .................................................................................................................. 7 
2.2 Cell Culture ............................................................................................................. 7 
2.3 qRT-PCR ................................................................................................................. 8 
2.4 Cytotoxicity Assay ................................................................................................... 8 
2.5 Critical Micelle Concentration (CMC) ................................................................. 9 
2.6 Kynurenine Inhibition Measurement Assay ........................................................ 9 
2.7 Animals .................................................................................................................. 10 
 vii 
2.8 Synthesis of PEG5k-(Fmoc-NLG)2 ....................................................................... 10 
3. RESULTS .................................................................................................................... 13 
3.1 Treatment by Anticancer Drugs on IDO Expression. ....................................... 13 
3.2 Combination Treatment of PTX and IMA on IDO Expression. ...................... 14 
3.3 Combinational Treatment of PTX and IMA on Cancer Cell Growth. ............ 15 
3.4 Synthesis of PEG5k-(Fmoc-NLG)2 Conjugate. ................................................... 16 
3.5 Characterization of Drug-Loaded PEG5k-(Fmoc-NLG)2 Micelles. .................. 17 
3.5.1 Size Distribution and Morphology of Free Drug PEG5k-(Fmoc-NLG)2 
Micelles, PTX loaded Micelles and PTX, IMA Co-loaded Micelles. ...................... 17 
3.5.2 Stability Investigation of PEG5k-(Fmoc-NLG)2 Micelles. ............................... 19 
3.5.3 Critical Micellar Concentration (CMC) of PEG5k-(Fmoc-NLG)2 Micellar 
System. ......................................................................................................................... 20 
3.5.4 Kynurenine Inhibition Measurement of PEG5k-(Fmoc-NLG)2 Conjugate. .. 21 
3.5.5 In Vitro Cytotoxicity of Drug-loaded PEG5k-(Fmoc-NLG)2 Micelles. ........... 22 
3.6 In Vivo Therapeutic Study ................................................................................... 23 
3.7 RT-PCR Analysis of IDO Transcripts from tumor tissues. .................................. 26 
4. DISCUSSION .............................................................................................................. 28 
BIBLIOGRAPHY ........................................................................................................... 30 
 
 
 
 
 
 
 
 
 viii 
LIST OF TABLES 
Table 1. Phsicochemical characterization of drug-loaded PEG5k-(Fmoc-NLG)2 micellar 
system. ......................................................................................................................... 20 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 ix 
LIST OF FIGURES 
Figure 1. Overview of PEG5K-(Fmoc-NLG)2 conjugate as improved carrier for co-
delivery of Paclitaxel and Imatinib. .................................................................................... 6 
Figure 2. Synthesis scheme of PEG5k-(Fmoc-NLG)2 conjugate. ...................................... 10 
Figure 3. qRT-PCR analysis showing IDO expression of 4T1.2 cell treated with different 
anti-cancer agents including (A) PTX, (B) PTX plus ifn-γ, (C) IMA and (D) IMA plus 
ifn-γ, (E) DOX and (F) DAS. n= 3-4 each, significance determined by one-way ANOVA 
with Tukey’s post hoc test; p*<0.05, p**<0.01. All values are mean ± Standard 
Deviation. .......................................................................................................................... 14 
Figure 4. qRT-PCR analysis showing IDO expression of 4T1.2 cell treated with 
combination of PTX and IMA with (A) and without (B) ifn-γ induction. Concentration of 
ifn-γ = 50ng/ml. n= 3-4 each, significance determined by one-way ANOVA with Tukey’s 
post hoc test; p*<0.05, p**<0.01. All values are mean ± Standard Deviation. ................ 15 
Figure 5. Cytotoxicity of PTX and IMA combinational treatment on 4T1.2 cell line 
showing no synergistic effect between these two anti-cancer agents. The experiment were 
repeated four times. Results are showing in mean ± Standard Deviation. ....................... 16 
Figure 6. 
1
H-NMR of PEG5k-(Fmoc-NLG)2 conjugate .................................................... 17 
Figure 7. (A,B) Size distribution and morphology of free drug PEG5k-(Fmoc-NLG)2 
micelles; (C,D) PTX-loaded PEG5k-(Fmoc-NLG)2 micelles; (E,F) PTX+IMA-loaded 
PEG5k-(Fmoc-NLG)2 micelles; ......................................................................................... 18 
Figure 8. Critical micelle concentration (CMC) of PEG5k-(Fmoc-NLG)2 micelle. .......... 21 
 x 
Figure 9. NLG and PEG5k-(Fmoc-NLG)2 conjugate potently inhibit kynurenine 
production at a dose-dependent manner in ifn-γ-treated Hela cells. Concentration of ifn-
γ= 50 ng/mL. The experiment was performed in triplicate and all values are mean ± 
Standard Deviation............................................................................................................ 22 
Figure 10. Cytotoxicity of PTX-loaded PEG5k-(Fmoc-NLG)2, IMA-loaded PEG5k-(Fmoc-
NLG)2 and PTX+IMA-loaded PEG5k-(Fmoc-NLG)2 micelles in comparison to Taxol 
formulation in various types of tumor cells including (A) 4T1.2, (B) PANC-2, (C) MCF-7 
and (D) PC-3. The experiment was performed in triplicate and all values are mean ± 
Standard Deviation............................................................................................................ 23 
Figure 11. (A) In vivo therapeutic study of drug free PEG5k-(Fmoc-NLG)2, PTX-loaded 
PEG5k-(Fmoc-NLG)2, IMA-loaded PEG5k-(Fmoc-NLG)2 and PTX+IMA-loaded PEG5k-
(Fmoc-NLG)2 micelles in comparison to Taxol formulation on 4T1.2 bearing BALB/c 
mice model. n=4-5 each group. Injection was given on day 0, 2, 4, 7 and 10 respectively. 
(B) Changes of body weight in mice that received different treatments. (C) Observation 
of tumor size from each group. (D) Average tumor weight from each group. Significance 
determined by one-way ANOVA with Fisher’s post hoc test; p*<0.05, p**<0.01, 
p***<0.001. All values are mean ± S.E.M ....................................................................... 26 
Figure 12. qRT-PCR analysis showing  IDO mRNA from mouse 4T1.2 tumor tissues 
(n=4-5 each group). All values are mean ± S.E.M ........................................................... 27 
 1 
1. INTRODUCTION 
1.1 Limitations of current anticancer drugs and effective drug delivery system for 
cancer treatment. 
Chemotherapy, designed to use drugs directly kill cancer cells, is one of the major 
approaches to treat cancer. It can be used alone or in the combination with several other 
forms of therapy. Paclitaxel (PTX) is one of the first-line chemo drugs for treatment of 
ovarian, breast, lung, pancreatic and other cancers. However, clinical application of PTX 
has been suffered from low aqueous solubility, rapid elimination and lack of selectively. 
1
 
Taxol is a Cremophor EL/ethanol formulation of PTX that has been used in clinic. But 
Cremophor EL can cause hyperactivity reaction, neuropathy and many other severe side 
effects. For these reasons, it is necessary to develop an alternative delivery system not 
only to defeat these limitations but also increase the potency of anticancer agents. Micelle, 
one of the nanocarriers, is an aggregate of amphiphilic molecules dispersed in the 
aqueous solution.
2
  A typical micelle has a hydrophilic head outside and hydrophobic tail 
regions inside the structure. Polyethylene glycol (PEG) is a safe, non-toxic, highly 
hydrated and biodegradable polymer with many applications in medicine, which can also 
be utilized as classic hydrophilic head of the micellar system. The incorporation of chemo 
drugs into micellar systems has several advantages such as relatively small size (10-
100nm),
3
  increased bioavailability and passively targeted to the tumor sites by the 
enhanced permeability and retention (EPR) effect.
4,5
 The hydrophilic shell of the PEG-
derivatized micellar system provides steric stability by preventing the recognition and 
binding of plasma protein, further avoiding uptake by the reticuloendothelial system 
 2 
(RES).
3
 In addition, the versatility of PEG-derivatized micellar system can be utilized as 
a platform for a broad range of chemo drugs with different structures. 
1.2 Stimulated immune response by conventional chemotherapy. 
Generally, most chemo drugs lead to death of all fast dividing cells including both tumor 
cells and healthy cells. However, accumulating evidence indicates that chemo drug can 
stimulate the host immune system that cooperates for successful tumor elimination.
6,7
 In 
response to chemotherapy, the dying tumor cells will expose Calreticulin (CRT) on the 
outer leaflet of their plasma membrane at a preapoptotic stage, secret Adenosine 
Triphosphate (ATP) during apoptosis and release nuclear protein high-mobility group 
box 1 (HMGB1) to facilitate the activation of dendritic cells (DCs) and T cells to further 
induce cytotoxic T cells to kill tumor cells.
8
  
 
1.3 Immune checkpoints modulate immune escape during cancer progression. 
Although chemotherapy can stimulate immune response, such response exhibits some 
limitations; one of them is due to the immune checkpoints. The immune checkpoints are 
negative regulators of the immune system. Normally, they paly critical roles in 
maintaining self-tolerance and protecting tissues from immune collateral damage when 
the immune system responses to pathogenic infection.
9
 These immune checkpoints can 
also be co-opted by tumor cells to escape from the immune destruction. Blocking those 
immune checkpoints is thus a promising approach to enhance anti-tumor immunity. 
There are several immune checkpoints that have been actively studies to the context of 
clinical cancer immunotherapy, including cytotoxic T-lymphocyte-associated antigen 4 
 3 
(CTLA4), programmed cell death protein 1 (PD-1) and Indoleamine-2,3-dioxygenase 
(IDO).
10
 They can regulate immune response at different levels with different 
mechanisms. Because both the role of CTLA4 and PD-1 are initiated by ligand-receptor 
interactions, they can be readily blocked by antibodies.
11,12
 CTLA4 antibody Ipilimumab 
(Yevoy
®
) and PD-1 antibodies Nivolumab (Opdivo
®
) and Iambrolizumab (Keytruda
®
) 
have been approved by US Food and Drug and Administration (FDA). 
 
1.4 Indoleamine-2,3-dioxygenase (IDO) can be used as one therapeutic target to 
enhance immune response. 
Indoleamine-2,3-dioxygenase (IDO) is the initial and rate-limiting enzyme of tryptophan 
catabolism along the kynurenine pathway.
13
 Initially the role of IDO was thought to be 
mainly antimicrobial by reducing the availability of the essential amino acid tryptophan 
in the inflammatory environment.
14-16
 The earliest studies of IDO related to cancer were 
made in 1950s that researchers observed tryptophan catabolites are elevated in cancer 
patients. Next a groundbreaking discover work was done in 1998 by Munn’s group.17,18 
Their study, for the first time, showed that IDO might mediate immunosuppression based 
on the preferential sensitivity of T cells to tryptophan deprivation. IDO is overexpressed 
by antigen presenting cells in many cancers. Its activity leads to the deficiency of local 
tryptophan and production of tryptophan metabolites, such as kynurenine, which have 
been shown to have immunosuppression effects including promoting Treg cell 
differentiation, blocking T-lymphocyte proliferation, suppressing immune response and 
decreasing Dendritic cell (DC) function.
19,20
 Several studies also showed that IDO can be 
induced by ifn-γ, an inflammatory cytokine, through JAK-STAT signaling pathway.21 
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Therefore, a number of chemicals and other small molecules have been developed to act 
as IDO inhibitors. NLG919 (NLG), a potent specific enzymatic inhibitor of IDO, is 
already in the clinical Phase I trial.
22
  
 
1.5 PEG-Fmoc-NLG conjugates as dual-function carriers for cancer targeted 
delivery. 
 9-fluorenylmethoxycarbonyl (Fmoc) moiety, a functional group routinely used for amino 
acid protection, was demonstrated as one of the most potent drug-interactive motif. The 
incorporation of Fmoc motif into PEG-drug conjugates can increase both the drug-
loading capacity and formulation stability.
23,24
 Previously, a PEG2k-Fmoc-NLG conjugate 
was developed by our group, which can work as a functional carrier to deliver anticancer 
drug Paclitaxel (PTX) specifically to the tumor site. Meanwhile, the release of NLG can 
inhibit the activity of IDO and help to re-establish an immunogenic response to cancer. In 
vivo study in a 4T1.2 murine breast cancer tumor model has shown enhanced effect of 
chemotherapy to reduce tumor growth compared with commercial formulation Taxol
®
.  
 
1.6 IDO expression inhibitor can work synergistically with PEG detrivatised NLG 
based micellar system. 
Although PTX-loaded PEG2k-Fmoc-NLG micelles showed enhanced antitumor activity, 
we found out both the carrier and PTX-loaded micelles induced an up-regulation of IDO 
expression at the mRNA level. We believe this is due to the negative feedback 
mechanism. NLG is known as an enzymatic inhibitor of IDO. Thus, decrease in the 
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amount of enzymatic metabolites would cause an increase in the expression of  the 
enzyme. For long-term treatment, increased dose of this formulation would be necessary 
to maintain the same effect for treating cancer. , PTX could also induce the ifn-γ, which, 
in turn, leads to further induction of IDO.  Imatinib is the first generation Bcr-Abl 
tyrosine kinase inhibitor mainly used to treat chronic myelogenous leukemia (CML).
25-27
 
A recent study reported that Imatinib showed an inhibitory effect on IDO expression, 
which potentiates antitumor T cell response in gastrointestinal stromal tumor (GIST).
26
 
We hypothesized that addition of Imatinib into our current combination protocol shall 
represent a more effective immunochemotherapy via inhibiting IDO at both 
transcriptional and enzymatic levels.  
.  
 6 
1.7 Overview of thesis. 
 
 
Figure 1. Overview of PEG5K-(Fmoc-NLG)2 conjugate as improved carrier for co-delivery of Paclitaxel and 
Imatinib. 
 
Hence, in this thesis, we first examined the effect on IDO expression by several 
anticancer drug treatments in cancer cell lines and confirmed the down-regulation effect 
of Imatinib on IDO expression. Secondly, we successfully synthesized an improved PEG-
NLG-based carrier, PEG5K-(Fmoc-NLG)2 for co-delivery of PTX and IMA. Finally, the 
new micellar system was extensively characterized with respect to both biophysical 
properties and the therapeutic efficacy in a murine breast cancer model (4T1.2). 
PEG
5K
-(Fmoc-NLG)
2
  
Paclitaxel (PTX) 
Imatinib (IMA) 
Self-assemble 
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2. MATERIALS AND METHODS 
2.1 Materials 
Poly(ethylene glycol) methyl ether (MeO−PEG−OH, MW = 5000 kDa), dichloromethane 
(DCM), Dimethyl sulfoxide (DMSO), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide (MTT), Nile Red, p-dimethylamino benzaldehyde, trichloroacetic 
acid (TCA), Acetic Acid and Dulbecco’s Modified Eagle’s Medium (DMEM) were all 
purchased from Sigma-Aldrich (MO, U.S.A). Boc-Lys(Boc)-OH and Fmoc-Lys(Boc)-
OH were purchased from GL Biochem (Shanghai, China). Succinic Anhydride was 
purchased from TCI AMERICA (OR, USA). Dicyclohexylcarbodiimide (DCC) and 
Trifluoroacetic Acid (CF3COOH) were purchased from Alfa Aesar (MA, USA). 4-
(dimethylamino) pyridine (DMAP) was purchased from Calbiochem-Novabiochem 
Corporation (CA, USA). Tiethylamine (TEA) was purchased from Acros Organic (NJ, 
USA).  Fetal bovine serum (FBS) and penicillin−streptomycin solution were purchased 
from Invitrogen (NY, USA). TRIzol Reagent was purchased from life technologies (CA, 
USA). All solvents used in this study were HPLC grade. 
 
2.2 Cell Culture 
Hela is a human cervical cancer cell line. MCF-7 is a human breast carcinoma cell line. 
PC-3 is a human prostate cancer cell lines. 4T1.2 is a mouse metastatic breast cancer cell 
line and PANC-2 is a mouse pancreatic cancer cell line. All cell lines were cultured in 
DMEM containing 10% FBS and 1% penicillin−streptomycin at 37 °C in a humidified 
5% CO2 atmosphere. 
 8 
 
2.3 qRT-PCR 
For in vitro investigation, 4T1.2 cell (15000 cells/well) were seeded in 6-well plates 
followed by 24 h of incubation in DMEM with 10% FBS and 1% streptomycin/penicillin. 
Then, various concentration of free PTX, IMA, Doxorubicin (DOX), Dasatinib (DAS) 
and the combination of PTX and IMA respectively were added and cells were incubated 
in DMEM with 2% FBS and 1% streptomycin/penicillin for 16~20h. Next we extracted 
total RNA, reverse-transcribed using High-Capacity cDNA Reverse Transcription Kit 
purchased form Thermo Fisher (MA, USA) and amplified cDNA with PCR SYBR Green 
probes for mouse genes encoding ifn-γ, IDO and GAPDH (Eurofins, Luxembourg). 
 
2.4 Cytotoxicity Assay 
MCF-7 (4000 cells/well), PC-3 (2000 cells/well), 4T1.2 (1000 cells/well) and PANC-2 
(1000 cells/well) were seeded in 96-well plates followed by 24 h of incubation in DMEM 
with 10% FBS and 1% streptomycin/penicillin. Then, various concentrations of free PTX 
or free IMA and the combination of both respectively were added in triplicate and cells 
were incubated in DMEM with 2% FBS and 1% streptomycin/penicillin for 72 h. After 
removing the medium in the plates, 100 μL of 3-(4, 5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazoliumbromide (MTT) in 0.9% Saline was added and cells were further 
incubated for 4 h. After removing the medium in the plates, MTT formazan was 
solubilized by DMSO. The absorbance of each well was measured by the microplate-
reader, with wavelength at 550 nm and reference wavelength at 630 nm. Untreated 
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groups were served as controls. Cell viability was calculated as [(ODtreat − 
ODblank)/(ODcontrol − ODblank) × 100%]. Same assay was also applied for micelles (Carrier, 
PTX/Carrier, IMA/Carrier, PTX+IMA/Carrier and Taxol) cytotoxicity test on these cell 
lines.  
 
2.5 Critical Micelle Concentration (CMC) 
The CMC of PEG5k-(Fmoc-NLG)2 micelles were measured using nile red as a 
fluorescence probe with final concentration of 1.25nM. Nile red fluorescence was 
measured at 25℃ using an excitation wavelength between 490 and 590 nm. Fluorescent 
emission was measured from 550 to 700nm at 5 nm intervals.
28
  
 
2.6 Kynurenine Inhibition Measurement Assay 
Hela (2000 cells/well) were seeded in 96-well plates followed by 24 h of incubation in 
DMEM with 10% FBS and 1% streptomycin/penicillin. Then, various concentration of 
NLG or PEG5k-(Fmoc-NLG)2 were added to the cell together with ifn-γ (50ng/mL) for 2 
days. Next, we collect 100μL of the cell culture supernatant and add 50μL 30% w/v 
trichloroacetic acid (TCA) and incubated for 40 min at 50°C to hydrolyze N-
formylkynurenine to kynurenine. After centrifugation at 3000 rpm for 10 min, 100μL of 
the supernatant were transferred into a new 96-well plate and mixed with 100μL 2% w/v 
p-dimethylamino benzaldehyde in 99/8% v/v acetic acid. After incubation for 10 min at 
room temperature. Kynurenine was detected by measuring the absorbance at 490nm. The 
absorbance of the culture medium alone without any treatment was considered as blank.
28
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2.7 Animals 
Female BALB/c mice, 4-6 weeks in age, were purchased from Charles River (Davis, 
CA). All animals were housed under pathogen-free conditions according to AAALAC 
guidelines. All animal-related experiments were performed in full compliance with 
institutional guidelines and approved by the Animal Use and Care Administrative 
Advisory Committee at the University of Pittsburgh. 
 
2.8 Synthesis of PEG5k-(Fmoc-NLG)2 
Figure 2 shows the synthesis route of PEG5k-(Fmoc-NLG)2 conjugate. 
 
 
Figure 2. Synthesis scheme of PEG5k-(Fmoc-NLG)2 conjugate. 
 
Step 1: Preparation of MeO-PEG5k-di-Boc-lysine 
MeO-PEG5k-OH (5g, 1 mmol, 1.0 eq), (S)-2,6-Bis-tert-butoxycarbonylaminohexanoic 
acid (Boc-Lys(Boc)-OH) (2.08g, 6.0 mmol, 6.0 eq), DCC (1.236g, 6mmol, 6 eq) and 
 11 
DMAP (37mg, 0.3 mmol, 0.3 eq) were dissolved in DCM and stirred at room temperature 
for two days. The mixture was filtered through cotton and then purified through two 
cycles of dissolution/reprecipitation with DCM/ether and DCM/ethanol respectively to 
afford MeO-PEG5k-di-Boc-lysine (4.5 g, 0.8 mmol, 84% yield). 
 
Step 2: Preparation of MeO-PEG5k-lysine-(NH2)2 
MeO-PEG5k-di-Boc-lysine (4.5g, 0.87 mmol) was dissolved in 20 mL mixture of 
trifluoroacetic acid (TFA) (50% in volume)/DCM. The mixture was stirred for 2 hours at 
room temperature and purified through three cycles of dissolution/reprecipitation with 
DCM/ether to give MeO-PEG5k-Boc-lysine-(NH2)2 (4.0 g, 0.8 mmol, 97% yield). 
 
Step 3: Preparation of MeO-PEG5k-lysine-Fmoc2-di-Boc-lysine 
MeO-PEG5k-lysine-(NH2)2  (4.0 g, 0.8 mmol, 1.0 eq), Fmoc-Lys(Boc)-OH (2.12g, 4.8 
mmol, 6.0 eq), DCC (0.93mg, 4.8mmol, 6.0 eq) and DMAP (27mg, 0.24 mmol, 0.3 eq) 
were dissolved in 20 mL DCM and stirred for 2 days at room temperature. The mixture 
was filtered through cotton and then purified through two cycles of 
dissolution/reprecipitation with DCM/ether and DCM/ethanol respectively to afford 
MeO-PEG5k-lysine-Fmoc2-di-Boc-lysine (3.8 g, 0.66 mmol, 91% yield). 
 
Step 4: Preparation of MeO-PEG5k-lysine-Fmoc2-lysine-(NH2)2 
MeO-PEG5k-lysine-Fmoc2-di-Boc-lysine was dissolved in 20 mL mixture of 
trifluoroacetic acid (TFA) (50% in volume)/DCM. The mixture was stirred for 2 hours at 
room temperature and purified through three cycles of dissolution/reprecipitation with 
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DCM/ether to give MeO-PEG5k-lysine-Fmoc2-lysine-(NH2)2 (3.5 g, 0.6 mmol, 90% 
yield). 
 
Step 5: Preparation of MeO-PEG5k-lysine-Fmoc2-lysine-COOH2 
MeO-PEG5k-lysine-Fmoc2-lysine-(NH2)2 (3.5 g, 0.7 mmol, 1.0eq), succinic anhydride 
(240 mg, 2.8 mmol, 4.0 eq), DMAP (290 mg, 2.8 mmol, 4.0 eq) were dissolved in 20 mL 
DCM and stirred overnight at room temperature. The mixture was purified through two 
cycles of dissolution/reprecipitation with DCM/ether and DCM/ethanol respectively to 
afford MeO-PEG5k-lysine-Fmoc2-lysine-COOH2 (3.0 g, 0.5 mmol, 85% yield). 
 
Step 6: Preparation of PEG5k-(Fmoc-NLG)2 
MeO-PEG5k-lysine-Fmoc2-lysine-COOH2 (250mg, 0.0414mmol, 1.0eq), NLG919 (70mg, 
0.24mmol, 6.0eq), DCC (51.2mg, 0.248mmol, 6.0eq), DMAP (5mg, 0.041mmol, 6.0eq) 
were dissolved in 1 mL DCM and stirred for 2 days at room temperature. The mixture 
was purified through two cycles of dissolution/reprecipitation with DCM/ether and 
DCM/ethanol respectively to afford PEG5k-(Fmoc-NLG)2 (200mg, 0.03mmol, 86% yeild) 
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  3. RESULTS 
3.1 Treatment by Anticancer Drugs on IDO Expression.  
In consistent with previous reports
29
, ifn-γ treatment led to a significant induction of IDO 
1 mRNA expression (Fig. 3B). PTX treatment also showed a modest effect in inducting 
the IDO 1 expression (Fig. 3A) The combination of the two showed an effect that was 
more dramatic than the one with each treatment alone (Fig. 3B).  
Dox or Das treatment also showed some effect in inducing the expression of IDO1 
mRNA (Fig. 3E, F). In contrast, IMA treatment significantly inhibited both basal and 
IFN- γ induced IDO1 mRNA expression (Fig. 3C, D). 
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Figure 3. qRT-PCR analysis showing IDO expression of 4T1.2 cell treated with different anti-cancer agents 
including (A) PTX, (B) PTX plus ifn-γ, (C) IMA and (D) IMA plus ifn-γ, (E) DOX and (F) DAS. n= 3-4 
each, significance determined by one-way ANOVA with Tukey’s post hoc test; p*<0.05, p**<0.01. All 
values are mean ± Standard Deviation. 
 
3.2 Combination Treatment of PTX and IMA on IDO Expression. 
After demonstrating the inhibitory effect of IMA on IDO1 expression, we then 
investigated whether IMA could also inhibit the PTX-induced IDO1 expression under 
both basal condition and stimulation by IFN- γ. In consistent with the data in Figure 3, 
PTX treatment led to significant induction of IDO1 mRNA, particularly in combination 
with IFN- γ. However this induction was significantly inhibited via co-treatment with 
IMA. 
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Figure 4. qRT-PCR analysis showing IDO expression of 4T1.2 cell treated with combination of PTX and 
IMA with (A) and without (B) ifn-γ induction. Concentration of ifn-γ = 50ng/ml. n= 3-4 each, significance 
determined by one-way ANOVA with Tukey’s post hoc test; p*<0.05, p**<0.01. All values are mean ± 
Standard Deviation. 
3.3 Combinational Treatment of PTX and IMA on Cancer Cell Growth. 
The cytotoxicity of PTX and IMA co-treatment effect was examined on 4T1.2 cell line. 
When the cell line was treated with PTX and IMA, there was a dose-depended inhibition 
of cell proliferation. With fixed concentration of PTX, especially at the concentration 
below IC50, addition of IMA did not lead to enhanced growth inhibition, suggesting lack 
of synergy between PTX and IMA on 4T1.2 tumor cells. 
 
 
 
* 
* * * 
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Figure 5. Cytotoxicity of PTX and IMA combinational treatment on 4T1.2 cell line showing no synergistic 
effect between these two anti-cancer agents. The experiment were repeated four times. Results are showing 
in mean ± Standard Deviation. 
3.4 Synthesis of PEG5k-(Fmoc-NLG)2 Conjugate. 
Our previous carrier, PEG2k-Fmoc-NLG was effective in delivery of PTX but was not 
capable of codelivery of PTX and IMA. We believed that this was likely due to the 
limited size of drug-interactive pocket. We hypothesized that a similar carrier with an 
expanded drug-interactive pocket such as PEG5k-(Fmoc-NLG)2 shall be more effective in 
co-formulating PTX and IMA. PEG5k-(Fmoc-NLG)2 was synthesized through 6 steps 
and
1
H-NMR spectrum is shown in Figure 6. Signals at 3.63 ppm are attributable to the 
methylene protons of PEG. Signals at 7-8 ppm are attributable benzene ring protons of 
Fmoc motif and protons of NLG. Signal at 5.3-5.4 ppm represents for the protons of NLG. 
Signals from 1 ppm to 1.5 ppm are attributable to the cyclohexane of NLG. These data 
suggest successful preparation of PEG5k-(Fmoc-NLG)2. 
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Figure 6. 
1
H-NMR of PEG5k-(Fmoc-NLG)2 conjugate 
3.5 Characterization of Drug-Loaded PEG5k-(Fmoc-NLG)2 Micelles. 
3.5.1 Size Distribution and Morphology of Free Drug PEG5k-(Fmoc-NLG)2 Micelles, 
PTX loaded Micelles and PTX, IMA Co-loaded Micelles. 
Our PEG5k-(Fmoc-NLG)2 conjugate can readily formed micelles in aqueous solution. 
Dynamic light scanning (DLS) measurements showed that our micelles either carrier 
alone or loaded with drugs had hydrodynamic size around 100 to 120 nm. Transmission 
electron microscopy (TEM) image showed our micelles were spherical particles with a 
uniform size distribution. 
                                                                                                
 18 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. (A,B) Size distribution and morphology of free drug PEG5k-(Fmoc-NLG)2 micelles; (C,D) PTX-
loaded PEG5k-(Fmoc-NLG)2 micelles; (E,F) PTX+IMA-loaded PEG5k-(Fmoc-NLG)2 micelles; 
 
A B 
C D 
E F 
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3.5.2 Stability Investigation of PEG5k-(Fmoc-NLG)2 Micelles. 
A minimal carrier/drug ratio of 0.5:1 was required to load PTX into PEG5k-(Fmoc-NLG)2 
micelles and the particles were stable for ~2 hour at room temperature and ~8 hour at 
4℃. For loading of IMA, the minimal carrier/drug ratio was 1:1 and the particles were 
stable for about 1 day at room temperature. Increasing the carrier/drug ratio was 
associated with a significant improvement in the stability of drug-loaded micelles at both 
room temperature and 4℃. At a carrier to drug ratio of 5:1:1 molar ratio of carrier to drug 
can successfully load two drugs and stabilize for 60 hours.  The detailed data on drug 
loading capacity and formulation stability are shown in table 1. 
Micelles
a
 
Molar 
Ratio 
Stability  
(RT) 
Stability 
(4℃) 
DLC
b
 (%) 
PTX 
DLC (%) 
IMA 
PEG5k-(Fmoc-NLG)2: PTX 0.5:1 6 h 12 h 20.8 -- 
PEG5k-(Fmoc-NLG)2: PTX 1:1 24 h 7 d 11.6 -- 
PEG5k-(Fmoc-NLG)2: PTX 2.5:1 2 d 40 d 5 -- 
PEG5k-(Fmoc-NLG)2: PTX 5:1 3 d 43 d 2.6 -- 
PEG5k-(Fmoc-NLG)2: IMA 1:1 18 h 5 d -- 7.3 
PEG5k-(Fmoc-NLG)2: IMA 2.5:1 5 d 7 d -- 3.2 
PEG5k-(Fmoc-NLG)2: IMA 5:1 14 d 36 d -- 1.5 
PEG5k-(Fmoc-NLG)2: IMA: PTX 1:1:1 18 h 5 d 11 6.3 
PEG5k-(Fmoc-NLG)2: IMA: PTX 2.5:1:1 24 h 14 d 4.9 2.8 
PEG5k-(Fmoc-NLG)2: IMA: PTX 5:1:1 60 h 30 d 2.5 1.5 
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Table 1. Phsicochemical characterization of drug-loaded PEG5k-(Fmoc-NLG)2 micellar 
system. 
a
 PTX concentration in micelles was kept at 1 mg/mL and IMA concentration in micelles was kept at 0.58 
mg/mL. 
b
 DLC = drug loading capacity. DLC (%) = [weight of drug loaded/ (weight of polymer + drug 
used)] × 100 
 
3.5.3 Critical Micellar Concentration (CMC) of PEG5k-(Fmoc-NLG)2 Micellar 
System. 
CMC is defined as the concentration of surfactants above which micelles form. The CMC 
of PEG5k-(Fmoc-NLG)2 micelle was measured using nile red as a fluorescence probe. 
When the concentration of the PEG5k-(Fmoc-NLG)2 reached the CMC, the fluorescence 
intensity of nile red would change dramatically due to the transfer of nile red from polar 
microenvironment to nonpolar surroundings caused by the encapsulation into the core of 
our micellar system. The CMC of PEG5k-(Fmoc-NLG)2 was determined to be 0.66 μM by 
crossover point at the low concentration range, which was similar to our previous carrier 
PEG2k-Fmoc-NLG (0.737 μM) . The relatively low CMC may render the PEG5k-(Fmoc-
NLG)2 micelles stable upon dilution in vivo. 
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Figure 8. Critical micelle concentration (CMC) of PEG5k-(Fmoc-NLG)2 micelle. 
3.5.4 Kynurenine Inhibition Measurement of PEG5k-(Fmoc-NLG)2 Conjugate. 
Hela cells can be induced by proinflammatory cytokines to express endogenous IDO, 
which consequently leads to production and secretion into culture medium of kynurenine. 
So we determine the ability of free NLG and PEG5k-(Fmoc-NLG)2 conjugate to inhibit 
the kynurenine production in recombinant ifn-γ-treated Hela cells. Figure 9 shows that 
free NLG inhibited kynurenine production in a concentration-dependent manner. PEG5k-
(Fmoc-NLG)2 conjugate was also effective in inhibiting the kynurenine production but 
less potently compared to free NLG.  
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Figure 9. NLG and PEG5k-(Fmoc-NLG)2 conjugate potently inhibit kynurenine production at a dose-
dependent manner in ifn-γ-treated Hela cells. Concentration of ifn-γ= 50 ng/mL. The experiment was 
performed in triplicate and all values are mean ± Standard Deviation. 
3.5.5 In Vitro Cytotoxicity of Drug-loaded PEG5k-(Fmoc-NLG)2 Micelles. 
The anti-tumor activities of PTX/PEG5k-(Fmoc-NLG)2, IMA/PEG5k-(Fmoc-NLG)2 and 
(PTX+IMA)/PEG5k-(Fmoc-NLG)2 micelles were examined in 4T1.2, PANC-2, MCF-7 
and PC-3 tumor cells and compared with Taxol. As shown in figure 10, Taxol inhibited 
the proliferation of several cancer cells at a concentration dependent manner. Delivery of 
PTX or PTX plus IMA via PEG5k-(Fmoc-NLG)2 micelles showed similar levels of 
cytotoxicity in all these four cancer cells, suggesting lack of synergy between the two 
drugs upon codelivery by PEG5k-(Fmoc-NLG)2 micelles.  
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Figure 10. Cytotoxicity of PTX-loaded PEG5k-(Fmoc-NLG)2, IMA-loaded PEG5k-(Fmoc-NLG)2 and 
PTX+IMA-loaded PEG5k-(Fmoc-NLG)2 micelles in comparison to Taxol formulation in various types of 
tumor cells including (A) 4T1.2, (B) PANC-2, (C) MCF-7 and (D) PC-3. The experiment was performed in 
triplicate and all values are mean ± Standard Deviation. 
3.6 In Vivo Therapeutic Study 
The antitumor activity of PTX-, IMA- and (PTX+IMA)-loaded PEG5k-(Fmoc-NLG)2 
micelles was evaluated in an aggressive breast cancer model (BALB/c bearing 4T1.2). 
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Since 4T1.2 grows at a very high proliferation rate, the PBS-treated control group 
displaced a rapid increase in tumor size during the experiment period. Both Taxol 
formulation (10mg PTX/kg) and drug-free PEG5k-(Fmoc-NLG)2 micelles showed modest 
effect in inhibiting the tumor growth. In contrast, PTX formulated in our PEG5k-(Fmoc-
NLG)2 micelles exhibited a much  more potent antitumor activity at the same dose. IMA 
(20 mg/kg) formulated in PEG5k-(Fmoc-NLG)2 micelles also showed a level of antitumor 
activity that was slightly higher than that of carrier alone. However, the most pronounced 
antitumor effect was obtained in the group of PTX and IMA co-delivery of PTX and 
IMA micelles group. In addition to significant tumor growth inhibition, the tumor in one 
mouse completely disappeared at the end of the treatment. All of the formulations were 
well tolerated and there were no significant differences in body weights among the 
different groups.  
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Figure 11. (A) In vivo therapeutic study of drug free PEG5k-(Fmoc-NLG)2, PTX-loaded PEG5k-(Fmoc-
NLG)2, IMA-loaded PEG5k-(Fmoc-NLG)2 and PTX+IMA-loaded PEG5k-(Fmoc-NLG)2 micelles in 
comparison to Taxol formulation on 4T1.2 bearing BALB/c mice model. n=4-5 each group. Injection was 
given on day 0, 2, 4, 7 and 10 respectively. (B) Changes of body weight in mice that received different 
treatments. (C) Observation of tumor size from each group. (D) Average tumor weight from each group. 
Significance determined by one-way ANOVA with Fisher’s post hoc test; p*<0.05, p**<0.01, p***<0.001. 
All values are mean ± S.E.M 
3.7 RT-PCR Analysis of IDO Transcripts from tumor tissues.  
The tumor tissues were collected at the end of the experiments and subjected to RT-PCR 
analysis of IDO mRNA expression. As shown in Figure 12, Taxol, PEG5k-(Fmoc-NLG)2 
micelles and PTX formulated micelles all showed induction effect on IDO expression 
while IMA formulated micelles and PTX+IMA co-loaded micelles all resulted in lower 
IDO expression level. 
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Figure 12. qRT-PCR analysis showing  IDO mRNA from mouse 4T1.2 tumor tissues (n=4-5 each group). 
All values are mean ± S.E.M 
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4. DISCUSSION 
Immunochemotherapy that combines the chemotherapeutic agents with the immune 
checkpoint inhibitors represents one of the attractive strategies for cancer treatment. We 
have recently developed a PEG-NLG-based dual functional carrier (PEG2k-Fmoc-NLG) 
that facilitates co-delivery of a chemotherapeutic agent (e.g., PTX) and NLG, a potent 
inhibitor of IDO. However, NLG inhibits IDO at the enzymatic level and this may 
activate the feedback mechanisms, which may lead to increased expression of IDO at 
transcriptional level and limit the overall efficacy of the treatment. Indeed, we showed 
that NLG treatment led to significant upregulation of IDO expression following treatment 
of the carrier alone. Interestingly, we have shown that chemotherapeutic agents such as 
PTX, DOX and DAS can also induce the expression of the IDO mRNA, particularly in 
combination with ifn-γ. The mechanism of ifn-γ induction by PTX and other anticancer 
agents is not clear at present. However, we showed PTX can trigger the ifn-γ response in 
tumor cells, which may subsequently contribute to the induction of the expression of IDO 
mRNA. 
  
Another interesting observation from this study is that the induction of IDO mRNA 
expression by PTX alone or in combination with ifn-γ, was significantly inhibited by 
IMA. We hypothesized that co-delivery of PTX and IMA by a PEG-NLG-based carrier 
shall represent a more effective strategy through inhibiting IDO at both enzymatic and 
transcriptional levels. Accordingly, an improved PEG-NLG-based carrier, PEG5k-(Fmoc-
NLG)2 was synthesized to facilitate co-delivery of PTX and IMA. PEG5k-(Fmoc-NLG)2 
was more effective than PEG2k-Fmoc-NLG in co-formulating PTX and IMA likely due to 
 29 
the increased size of the hydrophobic pocket. The increased number of Fmoc may also 
contribute to the more effective carrier/drug interaction. 
  
Co-delivery of IMA and PTX via PEG5k-(Fmoc-NLG)2 micelles led to a significant 
improvement in antitumor activity in vivo compared to IMA/PEG5k-(Fmoc-NLG)2 or 
PTX/PEG5k-(Fmoc-NLG)2. The improvement in therapeutic efficacy in the combination 
group is unlikely due to an additive effect from direct killing of tumor cells by each agent 
alone as the two agents showed no synergy in the in vitro cytotoxicity. This is likely 
attributed to a more drastic overall inhibition of IDO as supported by the significantly 
lower levels of IDO mRNA in the combination group compared to the group treated with 
PTX/PEG5k-(Fmoc-NLG)2. More studies are needed to better understand the underlying 
mechanism. 
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